Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
196 questions in 33 reviews · Urology
current versionsNo studies 196 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
NBI + WLC TURBT vs WLC TURBT Time to disease progression · transurethral resection of bladder tumors in people with suspected or diagnosed non‐muscle invasive bladder cancer Narrow band imaging versus white light cystoscopy alone for transurethral resection of non‐muscle invasive… (2022) · Cochrane | no estimate extracted | NR | No studies |
NBI + WLC TURBT vs WLC TURBT Time to death from bladder cancer · transurethral resection of bladder tumors in people with suspected or diagnosed non‐muscle invasive bladder cancer Narrow band imaging versus white light cystoscopy alone for transurethral resection of non‐muscle invasive… (2022) · Cochrane | no estimate extracted | NR | No studies |
Gemcitabine vs mitomycin Time to death from bladder cancer · participants with non‐muscle invasive bladder cancer1 (93 men, 16 women)Country: Italy Intravesical gemcitabine for non‐muscle invasive bladder cancer (2021) · Cochrane | no estimate extracted | NR | No studies |
Gemcitabine vs mitomycin Time to death from any cause · participants with non‐muscle invasive bladder cancer1 (93 men, 16 women)Country: Italy Intravesical gemcitabine for non‐muscle invasive bladder cancer (2021) · Cochrane | no estimate extracted | NR | No studies |
Gemcitabine vs mitomycin Disease‐specific quality of life · participants with non‐muscle invasive bladder cancer1 (93 men, 16 women)Country: Italy Intravesical gemcitabine for non‐muscle invasive bladder cancer (2021) · Cochrane | no estimate extracted | NR | No studies |
Gemcitabine vs BCG Time to death from any cause · participants with recurrent (1‐course BCG failure) high‐risk non‐muscle invasive bladder cancer (49 men, 31… Intravesical gemcitabine for non‐muscle invasive bladder cancer (2021) · Cochrane | no estimate extracted | NR | No studies |
Gemcitabine vs BCG Disease‐specific quality of life · participants with recurrent (1‐course BCG failure) high‐risk non‐muscle invasive bladder cancer (49 men, 31… Intravesical gemcitabine for non‐muscle invasive bladder cancer (2021) · Cochrane | no estimate extracted | NR | No studies |
Gemcitabine vs saline Disease‐specific quality of life · participants with non‐muscle invasive bladder cancer (607 men, 127 women)Country: Germany, Turkey, and the US Intravesical gemcitabine for non‐muscle invasive bladder cancer (2021) · Cochrane | no estimate extracted | NR | No studies |
Combination therapy vs anticholinergics Surgical intervention – not reported · men with lower urinary tract symptoms related to benign prostatic obstruction Anticholinergics combined with alpha‐blockers for treating lower urinary tract symptoms related to benign… (2021) · Cochrane | no estimate extracted | NR | No studies |
Combination therapy vs placebo Surgical intervention – not reported · men with lower urinary tract symptoms related to benign prostatic obstruction Anticholinergics combined with alpha‐blockers for treating lower urinary tract symptoms related to benign… (2021) · Cochrane | no estimate extracted | NR | No studies |
Degarelix vs standard androgen suppression therapy Overall survival · hormone‐sensitive prostate cancer Degarelix for treating advanced hormone‐sensitive prostate cancer (2021) · Cochrane | no estimate extracted | NR | No studies |
Degarelix vs standard androgen suppression therapy Cancer‐specific survival  · hormone‐sensitive prostate cancer Degarelix for treating advanced hormone‐sensitive prostate cancer (2021) · Cochrane | no estimate extracted | NR | No studies |
Ginseng vs placebo Quality of life ‐ not measured · men with ED Ginseng for erectile dysfunction (2021) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR TUMT (mixed estimate) · men with moderate to severe lower urinary symptoms due to benign prostatic hyperplasia Interventions: minimally… Minimally invasive treatments for lower urinary tract symptoms in men with benign prostatic hyperplasia: a… (2021) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR TIND (indirect estimate) · men with moderate to severe lower urinary symptoms due to benign prostatic hyperplasia Interventions: minimally… Minimally invasive treatments for lower urinary tract symptoms in men with benign prostatic hyperplasia: a… (2021) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR PAE (mixed estimate) · men with moderate to severe lower urinary symptoms due to benign prostatic hyperplasia Interventions: minimally… Minimally invasive treatments for lower urinary tract symptoms in men with benign prostatic hyperplasia: a… (2021) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR TUMT · men with moderate to severe lower urinary symptoms due to benign prostatic hyperplasia Interventions: minimally… Minimally invasive treatments for lower urinary tract symptoms in men with benign prostatic hyperplasia: a… (2021) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR TUMT (mixed estimate) · men with moderate to severe lower urinary symptoms due to benign prostatic hyperplasia Interventions: minimally… Minimally invasive treatments for lower urinary tract symptoms in men with benign prostatic hyperplasia: a… (2021) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR PAE (mixed estimate) · men with moderate to severe lower urinary symptoms due to benign prostatic hyperplasia Interventions: minimally… Minimally invasive treatments for lower urinary tract symptoms in men with benign prostatic hyperplasia: a… (2021) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR CRFWVT (Rezūm) (pairwise) · men with moderate to severe lower urinary symptoms due to benign prostatic hyperplasia Interventions: minimally… Minimally invasive treatments for lower urinary tract symptoms in men with benign prostatic hyperplasia: a… (2021) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR TIND (pairwise) · men with moderate to severe lower urinary symptoms due to benign prostatic hyperplasia Interventions: minimally… Minimally invasive treatments for lower urinary tract symptoms in men with benign prostatic hyperplasia: a… (2021) · Cochrane | no estimate extracted | NR | No studies |
Blue light vs white light Surgical complications, non‐serious (up to 90 days; MCID 5%) · people with non‐muscle invasive bladder cancer Blue versus white light for transurethral resection of non‐muscle invasive bladder cancer (2021) · Cochrane | no estimate extracted | NR | No studies |
Sunitinib vs avelumab + axitinib (targeted agent versus immunotherapy + targeted agent) Health‐related quality of life4 · Treatment‐naïve metastatic renal cell carcinoma (clear cell type) Targeted therapy for metastatic renal cell carcinoma (2020) · Cochrane | no estimate extracted | NR | No studies |
Sunitinib vs pembrolizumab + axitinib (targeted agent versus immunotherapy + targeted agent) Health‐related quality of life4 · Treatment‐naïve metastatic renal cell carcinoma (clear cell type) Targeted therapy for metastatic renal cell carcinoma (2020) · Cochrane | no estimate extracted | NR | No studies |
Sunitinib vs IMA901 + sunitinib (targeted agent versus tumour vaccine + targeted agent) Health‐related quality of life6 · Treatment‐naïve metastatic renal cell carcinoma (clear cell type) Targeted therapy for metastatic renal cell carcinoma (2020) · Cochrane | no estimate extracted | NR | No studies |
Sorafenib vs sunitinib (targeted agent versus targeted agent) Health‐related quality of life5 · Treatment‐naïve metastatic renal cell carcinoma (any cell type) Targeted therapy for metastatic renal cell carcinoma (2020) · Cochrane | no estimate extracted | NR | No studies |
Bevacizumab + IFN vs IFN (+ placebo) (targeted agent + classic immunotherapy versus classic immunotherapy) Health‐related quality of life3 · Treatment‐naïve metastatic renal cell carcinoma (clear cell type) Targeted therapy for metastatic renal cell carcinoma (2020) · Cochrane | no estimate extracted | NR | No studies |
Temsirolimus + bevacizumab vs bevacizumab + IFN‐α (targeted agent + targeted agent versus targeted agent + classic immunotherapy) Health‐related quality of life3 · Treatment‐naïve metastatic renal cell carcinoma (any cell type [80% clear cell]) Targeted therapy for metastatic renal cell carcinoma (2020) · Cochrane | no estimate extracted | NR | No studies |
Everolimus + bevacizumab vs IFN α‐2a + bevacizumab (targeted agent + targeted agent versus targeted agent + classic immunotherapy) Health‐related quality of life5 · Treatment‐naïve metastatic renal cell carcinoma (any cell type) Targeted therapy for metastatic renal cell carcinoma (2020) · Cochrane | no estimate extracted | NR | No studies |
Alpha‐blocker as adjuvant medical expulsive therapy plus usual care vs usual care Quality of life · adults with renal and ureteral stones undergoing shock wave lithotripsy Alpha‐blockers after shock wave lithotripsy for renal or ureteral stones in adults (2020) · Cochrane | no estimate extracted | NR | No studies |
Branch chain amino acids vs dextrose Length of hospital stay – not assessed Perioperative nutrition for the treatment of bladder cancer by radical cystectomy (2019) · Cochrane | no estimate extracted | NR | No studies |
Branch chain amino acids vs dextrose Mortality – not assessed Perioperative nutrition for the treatment of bladder cancer by radical cystectomy (2019) · Cochrane | no estimate extracted | NR | No studies |
Preoperative oral nutritional support vs normal diet Length of hospital stay – not measured Perioperative nutrition for the treatment of bladder cancer by radical cystectomy (2019) · Cochrane | no estimate extracted | NR | No studies |
Percutaneous nephrolithotripsy vs tubeless mini‐percutaneous nephrolithotripsy Serious adverse events or complications of treatment — not reported Medical and surgical interventions for the treatment of urinary stones in children (2019) · Cochrane | no estimate extracted | NR | No studies |
Alpha‐blockers vs placebo with/without analgesics Hospital stay — not reported Medical and surgical interventions for the treatment of urinary stones in children (2019) · Cochrane | no estimate extracted | NR | No studies |
Shock wave lithotripsy vs dissolution therapy Hospital stay — not reported Medical and surgical interventions for the treatment of urinary stones in children (2019) · Cochrane | no estimate extracted | NR | No studies |
Slow shock wave lithotripsy vs rapid shock wave lithotripsy Hospital stay — not reported Medical and surgical interventions for the treatment of urinary stones in children (2019) · Cochrane | no estimate extracted | NR | No studies |
5‐alpha reductase inhibitors vs placebo Sexual dysfunction ‐ not reported · men with chronic prostatitis/chronic pelvic pain syndrome Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome (2019) · Cochrane | no estimate extracted | NR | No studies |
5‐alpha reductase inhibitors vs placebo Quality of life ‐ not reported · men with chronic prostatitis/chronic pelvic pain syndrome Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome (2019) · Cochrane | no estimate extracted | NR | No studies |
5‐alpha reductase inhibitors vs placebo Anxiety and depression ‐ not reported · men with chronic prostatitis/chronic pelvic pain syndrome Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome (2019) · Cochrane | no estimate extracted | NR | No studies |
Antibiotic therapy vs placebo Anxiety and depression ‐ not reported · men with chronic prostatitis/chronic pelvic pain syndrome Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome (2019) · Cochrane | no estimate extracted | NR | No studies |
Anti‐inflammatories vs control Sexual dysfunction ‐ not reported · men with chronic prostatitis/chronic pelvic pain syndrome Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome (2019) · Cochrane | no estimate extracted | NR | No studies |
Anti‐inflammatories vs control Quality of life ‐ not reported · men with chronic prostatitis/chronic pelvic pain syndrome Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome (2019) · Cochrane | no estimate extracted | NR | No studies |
Anti‐inflammatories vs control Anxiety and depression ‐ not reported · men with chronic prostatitis/chronic pelvic pain syndrome Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome (2019) · Cochrane | no estimate extracted | NR | No studies |
Phytotherapy vs placebo or other agents Quality of life ‐ not reported · men with chronic prostatitis/chronic pelvic pain syndrome Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome (2019) · Cochrane | no estimate extracted | NR | No studies |
Phytotherapy vs placebo or other agents Anxiety and depression ‐ not reported · men with chronic prostatitis/chronic pelvic pain syndrome Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome (2019) · Cochrane | no estimate extracted | NR | No studies |
Botulinum toxin A vs placebo Sexual dysfunction ‐ not reported · men with chronic prostatitis/chronic pelvic pain syndrome Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome (2019) · Cochrane | no estimate extracted | NR | No studies |
Botulinum toxin A vs placebo Quality of life ‐ not reported · men with chronic prostatitis/chronic pelvic pain syndrome Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome (2019) · Cochrane | no estimate extracted | NR | No studies |
Botulinum toxin A vs placebo Anxiety and depression ‐ not reported · men with chronic prostatitis/chronic pelvic pain syndrome Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome (2019) · Cochrane | no estimate extracted | NR | No studies |
Allopurinol vs placebo Sexual dysfunction ‐ not reported · men with chronic prostatitis/chronic pelvic pain syndrome Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome (2019) · Cochrane | no estimate extracted | NR | No studies |